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Background: Many patients even those with health insurance pay out-of-pocket for medicines. We investigated
the availability and prices of essential medicines in the Boston area.
Methods: Using the WHO/HAI methodology, availability and undiscounted price data for both originator brand
(OB) and lowest price generic (LPG) equivalent versions of 25 essential medicines (14 prescription; 11 over-the-
counter (OTC)) were obtained from 17 private pharmacies. The inclusion and prices of 26 essential medicines in
seven pharmacy discount programs were also studied. The medicine prices were compared with international
reference prices (IRPs).
Results: In surveyed pharmacies, the OB medicines were less available as compared to the generics. The OB and
LPG versions of OTC medicines were 21.33 and 11.53 times the IRP, respectively. The median prices of prescription
medicines were higher, with OB and LPG versions at 158.14 and 38.03 times the IRP, respectively. In studied
pharmacy discount programs, the price ratios of surveyed medicines varied from 4.4–13.9.
Conclusions: While noting the WHO target that consumers should pay no more than four times the IRPs, medicine
prices were considerably higher in the Boston area. The prices for medicines included in the pharmacy discount
programs were closest to WHO’s target. Consumers should shop around, as medicine inclusion and prices vary
across discount programs. In order for consumers to identify meaningful potential savings through comparison
shopping, price transparency is needed.Background
Lack of regular access to essential medicines remains a
major public health concern globally. Essential medicines
are identified by the World Health Organization (WHO) as
those medicines which meet the global health needs of the
majority population. The WHO Model Essential Medicines
List is updated every two years in a transparent process [1].
While access has improved considerably since the introduc-
tion of the essential medicines concept in 1977, one-third
of the world’s population is still not treated with the needed
medicines [2–5]. Millar et al highlighted the potential value
of using the WHO Model Essential Medicines List to re-
duce costs and provide more equitable access to low-
income patients in the United States (US) [2].* Correspondence: richardl@bu.edu
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(http://creativecommons.org/publicdomain/zeIn low- and middle-income countries (LMICs), as many
as 90 % of the population pay out-of-pocket (OOP) for
their medicines [3, 6]. The US has also seen a shift to-
wards high-deductible insurance plans, within the last
decade. The majority (78 %) of plans, covering medical
procedures and prescription medicines, now have a gen-
eral deductible (the amount that must be paid OOP before
an insurer will pay any expenses), half of which are over
$1,000 [7]. Low medicine availability, high prices and poor
affordability are key barriers to medicine access [5, 8–12].
In many high-income countries including the US, there
are growing concerns about reduced medicine access for
reasons including high medicine prices and copayments/
deductibles, uninsured populations, lack of transparency
in medicine price components, and health agencies’ poor
ability to negotiate procurement prices [13–17].
In 2001, a resolution (WHA 54.11) endorsed by the
Member States of the World Health Assembly called foris distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
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to help improve access [18]. In response, the World
Health Organization/Health Action International (WHO/
HAI) Project on Medicine Prices and Availability was
established. The primary aim of this project was to de-
velop a standardized method to measure medicines’
prices, availability, affordability and price components in a
reproducible way so as to allow international comparisons
over time. In 2003, after testing in nine countries, the
standard WHO/HAI methodology was released, with a
second edition published in 2008 [19]. To assess the sur-
veyed medicines’ consumer prices, WHO/HAI method-
ology employs international reference prices (IRPs) as an
external benchmark. To measure prices, a median price
ratio (MPR) is calculated by comparing the median con-
sumer price of a given medicine with the respective IRP.
International reference prices used in this survey were
taken from the 2013 Management Sciences for Health
(MSH) International Drug Price Indicator Guide [20]. The
MSH reference prices, first published in 1986, are pro-
curement prices obtained from both sellers and buyers
and collected from government agencies, pharmaceutical
suppliers, and international development organizations.
The MSH prices are widely accepted as an appropriate
reference standard [9]. These MSH procurement prices
report the actual prices obtained by non-profit suppliers
and government tenders (see Additional file 1: List of
price sources for 2013 MSH Drug Price Indicator Guide),
the robust nature of this data ensures international com-
parability. Governments should be procuring medicines
on the international market at close to IRPs. But patient
prices in the private sector have to take into account add-
itional costs in the pharmaceutical supply chain (mark-
ups, tariffs, taxes and other costs). Because of these add-
itional costs, WHO has set a target of four times the IRP
for patient prices in the private sector. Recognizing medi-
cine availability and prices as important components of
access, the WHO medium term strategic plan 2008–2013
defines global and national targets for generic essential
medicines, targeting 80 % availability in all sectors and
median consumer prices to be no more than four times
the IRP [21].
The WHO/HAI Project has been successful in develop-
ing a standard method for measuring price, availability,
and affordability of essential medicines. As of 2014, more
than 100 surveys had been conducted across the world,
highlighting variations in medicine availability and prices
by region, therapeutic category, and sector [9, 22]. The
surveys provide transparency in price and availability
reporting and inform medicines procurement globally.
In 2009, Cameron et al reported on medicine availability
and prices in 36 developing and middle- income countries
[9]. A key finding was that in the private sector the aver-
age MPR of originator brands (OB) by economic regionvaried from 13.8 to 40.9. For generic medicines, the aver-
age MPR by economic region varied from 9.8 to 11. The
price ratios were adjusted for purchasing power parity.
In 2012, the US accounted for 35 % of the global
spending on medicines [23]. Americans face a high bur-
den of medicine expenditure owing to a combination of
unregulated prices and high OOP expenditures: an aver-
age per-capita OOP spending of USD 758 on medicines
in 2012 [24]. In 2014, an estimated 22 % of the patients
did not fill a prescription or skipped prescription doses
because of the cost [25]. Patients who are uninsured,
elderly, low income, or with high insurance copays are
disproportionately unlikely to fill their prescriptions [17].
Therefore, concerns about medicine access, especially
due to high prices, persist in the US.
There is a widespread perception that generic medi-
cines, which now represent 86 % of US prescriptions [7],
are available at competitive prices. While generics are
cheaper than the OB, the nature of generic price compe-
tition in the United States sometimes leads to aberra-
tions such as unexpected price hikes. For instance, the
price of daily average dose of albendazole, an older
broad spectrum anti-parasitic medicine, rose from USD
5.92 in 2010 to USD 11.96 in 2013, while it is less than
USD 1 in many countries [5].
Consumer Reports regularly investigates the availabil-
ity and prices of a limited number of generic medicines
across various pharmacy options available to consumers
in the US [24, 26–28]. They also compare the OB and
generic medicines across chain and independent phar-
macies, but do not compare consumer prices to the IRP.
In the relative absence of surveys of the actual prices
paid by consumers for prescription medicines in the US,
we believe our initial survey in the Boston area can indi-
cate whether the WHO/HAI methodology would be ap-
plicable, and allow comparisons with the studies
undertaken by Consumer Reports. Medicines included
in this survey are used globally, treat common condi-
tions, and appear on most US treatment guidelines.
Many of the surveyed medicines were included in the
2009 study of medicine availability and prices in 36 de-
veloping and middle-income countries [9].
Our Boston study investigated prices and availability of
OB and generic essential medicines across chain, inde-
pendent, big-box retail stores, and in-store supermarket
pharmacies. Prices were obtained for both generic and OB
products, and were then compared with the MSH IRPs.
To our knowledge, there are no peer-reviewed studies
assessing the availability and prices of OB and generic
medicines in the US using the WHO/HAI methodology.
Methods
A modified version of the WHO/HAI methodology was
employed. A typical WHO/HAI survey collects data on
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cines plus supplementary medicines chosen by the investi-
gator, and uses a standardized sampling frame including
public-sector health facilities and registered private-sector
retail pharmacies along with any other sector such as non-
governmental or mission hospitals. Since the US lacks
public sector distribution of medicines, we analyzed the
availability and prices of 25 essential medicines in a repre-
sentative sample of private-sector retail pharmacies (chain
and independent) and 26 essential medicines offered by
private-sector pharmacy and pharmacy discount programs
in the Boston area. Data on some additional medicines
were collected to provide a more robust sample of dis-
count schemes. The WHO/HAI methodology also as-
sesses the affordability of medicines, expressed as the
number of day’s wages required by the lowest paid un-
skilled government worker to purchase a month’s supply
of medicines for chronic conditions and a weeks’ supply
for acute conditions. Accurately identifying the wage of a
government worker in the Boston area is difficult hence
affordability was not assessed.
Sampling
Survey facilities
A list of currently licensed retail pharmacies (chain and inde-
pendent) in zip codes within the cities of Boston, Cambridge,
and Brookline was obtained from the Massachusetts Health
Care Safety and Quality website [29]. Systematic random
sampling was employed to select 10 chain pharmacies from
this list. Each was then matched to an independent phar-
macy in close proximity, resulting in a total survey sample
of 20 pharmacies. This study also included a sample of seven
pharmacy discount programs offered by big-box retail stores
as well as in-store or freestanding pharmacies, including
Walmart/Sam’s Club, Target, Hannaford, Walgreens, CVS,
and Jewel-Osco. These programs offer a selection of medi-
cines usually at prices of $4 per month or $10 for three
months. These programs were selected using non-
probability, convenience sampling and the price data were
collected, using public online sources, for the surveyed
medicines in these programs. See Additional file 1: Survey
facilities random sampling (methods) for further details.
Survey medicines
For the facility survey, 14 prescription medicines were
selected from the WHO/HAI global core medicines list,
and 11 commonly-used over-the-counter (OTC) medi-
cines. The survey basket for the pharmacy discount pro-
grams consisted of 26 medicines identified from WHO/
HAI global and regional (Latin America and the Carib-
bean) core medicine lists [3, 10]. All medicines were
strength and dosage-form specific. Table 1 lists the sur-
vey medicines. There were 14 medicines common to
both pharmacy facility and discount program surveys.All surveyed medicines are commonly used and have an
available IRP [9].Data collection, entry, cleaning, and analysis
After prior notification, the data collectors (Master of
Public Health (MPH) students undertaking practical
fieldwork) visited the selected pharmacy facilities and
identified themselves during October 2014. The data
collectors obtained information, by physically inspecting
the availability (in-stock) of the OB medicines and their
generic equivalents on the day of survey. The data col-
lectors also obtained information on the undiscounted
retail prices of the OB and the lowest price generics
(LPG) versions of the survey medicines using a stan-
dardized form developed by the WHO/HAI. These
prices reflect the amount in US dollars that a patient
without any health insurance or special medicine plan
would pay to purchase a given medicine.
For the pharmacy discount programs, price data were
obtained from public online sources during November
2014 (see Additional file 1: Pharmacy discount program
analysis (methods)). The medicine unit prices collected
from the facility survey were entered into the Excel-based
WHO/HAI Medicine Prices Workbook, followed by
double entry, automated and manual error-checking, and
built-in automated analysis feature of the workbook [19].
The pharmacy discount program data were entered and
analyzed using MS Excel. The facility survey workbooks
have been submitted to HAI and will be posted on the
HAI online price and availability database http://haiwe-
b.org/what-we-do/price-availability-affordability/.
In the case of the facility survey, medicine availability
is reported as the mean percentage of the retail pharma-
cies (overall and stratified by chain and independent)
where a given medicine was found. To facilitate inter-
national comparisons, medicine-specific median price
ratios (MPR) were calculated when prices were available
from at least four facilities. The MPR refers to the ratio
of a medicine’s local median unit price (across pharma-
cies) as compared to the 2013 MSH international me-
dian unit reference price [19, 20].
To summarize the MPRs of OB and LPG medicines, we
performed ‘all medicines’ and ‘matched pair’ MPR ana-
lyses, overall and by pharmacy-type. While the ‘all medi-
cines’ analysis considers all the available MPRs for each
survey medicine, the ‘matched pair’ analysis considers the
available MPRs for only those survey medicines which
existed in OB-LPG pairs. Using statistical software SAS
version 9.3, we conducted hypothesis testing to see if
availability and prices varied among pharmacies at alpha
significance of 0.05 (marginal significance if p-value be-
tween 0.05–0.06) (See Additional file 1: Statistical analysis:
facility medicine availability and prices (results)).
Table 1 List of medicines surveyed
Medicines Strength Dosage form/Unit Pack size (recommended)a Originator Brand
A. Over-the-counter medicines
Acetaminophen/Paracetamol 325 mg Tab/cap 100 Tylenol (McNeil)
Acetylsalicylic Acid 500 mg Tab/cap 100 Asprin (Bayer)
Cimetidine 200 mg Tab/cap 30 Tagamet (GSK)
Clotrimazole vaginal cream 1 % Gram 24 Clotrimin (MSD)
Diphenhydramine HCl 25 mg Tab/cap 100 Benadryl (McNeil)
Hydrocortisone topical cream 1 % Gram 51 –
Ibuprofen 200 mg Tab/cap 200 Advil (Pfizer)
Loratadine 10 mg Tab/cap 30 Claritin (MSD)
Miconazole Nitrate topical cream 2 % Gram 9 Monistat (McNeil)
Omeprazole 20 mg Tab/cap 42 Prilosec (AstraZeneca)
Ranitidine 150 mg Tab/cap 80 Zantac (Boehringer)
B. Prescription medicines
Amitriptyline 25 mg Tab/cap 100 Tryptizol (MSD)
Amoxicillin 500 mg Tab/cap 21 Amoxil (GSK)
Atenolol 50 mg Tab/cap 60 Tenormin (AstraZeneca)
Captopril 25 mg Tab/cap 60 Capoten (BMS)
Ceftriaxone injection 1 g/vial Vial 1 Rocephin (Roche)
Ciprofloxacin 500 mg Tab/cap 10 Ciproxin (Bayer)
Co-trimoxazole suspension 8 + 40 mg/ml Gram 100 Bactrim (Roche)
Diazepam 5 mg Tab/cap 100 Valium (Roche)
Diclofenac 50 mg Tab/cap 100 Voltarol (Novartis)
Glibenclamide 5 mg Tab/cap 60 Daonil (Sanofi-Aventis)
Omeprazole 20 mg Tab/cap 30 Losec (AstraZeneca)
Paracetamol (Acetaminophen) 24 mg/ml Milliliter 60 Panadol (GSK)
Salbutamol inhaler 100 mcg/dose Dose 200 Ventoline (GSK)
Simvastatin 20 mg Tab/cap 30 Zocor (MSD)
C. Pharmacy discount program medicines
Acute medicines
Amoxicillinb 500 mg Tab/cap 30 Amoxil (GSK)
Amoxicillin suspension 250 mg/5 ml Milliliters 150 ml Amoxil (GSK)
Azithromycin 500 mg Tab/cap 3 Zithromax (Pfizer)
Ceftriaxone Injectionb 1 g/vial Vial 1 Rocephin (Roche)
Ciprofloxacinb 500 mg Tab/cap 20 Ciproxin (Bayer)
Clotrimazole topical creamb 1 % Gram 15 gram tube Canesten (Bayer)
Diclofenacb 50 mg Tab/cap 60 Voltarol (Novartis)
Furosemide 40 mg Tab/cap 30 Lasix (Sanofi-Aventis)
Hydrochlorothiazide 25 mg Tab/cap 30 Dichlotride (MSD)
Ibuprofenb 400 mg Tab/cap 90 Brufen (Knoll)
Metronidazole 500 mg Tab/cap 14 Flagyl (Sanofi-Aventis)
Omeprazoleb 20 mg Tab/cap 30 Prilosec (AstraZeneca)
Ranitidineb 150 mg Tab/cap 60 Zantac (GSK)
Chronic medicines
Amitriptylineb 25 mg Tab/cap 90 Tryptizol (MSD)
Sharma et al. Journal of Pharmaceutical Policy and Practice  (2016) 9:12 Page 4 of 11
Table 1 List of medicines surveyed (Continued)
Amlodipine 5 mg Tab/cap 90 Norvasc (Pfizer)
Atenololb 50 mg Tab/cap 90 Tenormin (AstraZeneca)
Atorvastatin 10 mg Tab/cap 90 Lipitor (Pfizer)
Captoprilb 25 mg Tab/cap 180 Capoten (BMS)
Clonazepam 2 mg Tab/cap 90 Rivotril (Roche)
Diazepamb 5 mg Tab/cap 90 Valium (Roche)
Enalapril 10 mg Tab/cap 90 Renitec (MSD)
Fluoxetine 20 mg Tab/cap 90 Prozac (Eli Lilly)
Glibenclamideb 5 mg Tab/cap 90 Daonil (Sanofi-Aventis)
Metformin 850 mg Tab/cap 180 Glucophage (BMS)
Phenytoin 50 mg Tab/cap 90 Epanutin (Pfizer)
Simvastatinb 20 mg Tab/cap 90 Zocor (MSD)
aFor facility surveys (Table 1a-b), data collectors were instructed to obtain information for these medicine pack sizes (number of units). If not available, the
information for the size immediately larger was collected
bMedicines common to both the pharmacy survey and pharmacy discount scheme surveys
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cine availability is reported as the percentage of the
medicines included in pharmacy discount programs sur-
vey basket (See Table 1c) which were included in a given
program. Furthermore, we calculated medicine-specific
‘price ratio’ using the following formula:
Price Ratio ¼ Discount program unit price USDð Þ
MSH median unit international reference price USDð Þ
Results
The surveyed facilities varied in size, ranging from 720
to over 30,000 square feet. The space for pharmacy ser-
vices including dispensing and products ranged in size
from as much as 216 feet of shelf space for OTCs to no
OTC shelving at all. Of the total 20 pharmacies sampled,
data on OTC medicines were obtained from 17 pharma-
cies (10 chain; 7 independent). Only 14 pharmacies (8
chain; 6 independent) provided data on the prescription
medicines. Pharmacy staff ’s busy schedules or unwilling-
ness to cooperate appeared to be the main reasons for
the sample drop-outs in the case of prescriptionTable 2 Mean percentage availability of surveyed medicines in retai
Prescription medicines
Originator Brand
% (number of pharmacies)
Generic
% (number of pharma
Chain 52.7 % (n = 8) 78.6 % (n = 8)
Independent 28.6 % (n = 6) 76.6 % (n = 6)
Overall 42.3 % (n = 14) 78.6 % (n = 14)
Overall mean availability of originator brand (OB) and generic equivalent (GE) versio
0.24). However, the overall mean availability of OB and GE versions of prescription
versions of matched pairs was not statistically different (p-value > 0.05) from each oth
pharmacies. Mean availability of GE of OTC medicines was statistically different (p-va
significant difference (p-value = 1.0) in mean availability of GE of prescription medici
version were statistically different among chain and independent pharmacies, in casmedicines. However, some independent pharmacies even
refused to allow the collection of the OTC medicines in-
formation, which they referred to as “proprietary
information”.Facility survey: availability of surveyed medicines
Table 2 summarizes the availability of OTC and pre-
scription medicines, stratified by OB and generic equiva-
lents, in chain and independent pharmacies. In general,
the overall availability of OTC medicines was higher
than the prescription medicines. The OB medicines were
less available (prescription: 42.3 %; OTC: 73.8 %) as
compared to the generic equivalents (prescription:
78.6 %; OTC: 85.6 %). However, this difference was sta-
tistically significant for prescription medicines only. The
originator version of omeprazole was available in only
50 % of facilities; however the generic was available in
93 % of facilities. The OB version of OTC medicine clo-
trimazole, which was not available in any of the surveyed





% (number of pharmacies)
Generic
% (number of pharmacies)
80.9 % (n = 10) 94.5 % (n = 10)
63.6 % (n = 7) 72.7 % (n = 7)
73.8 % (n = 17) 85.6 % (n = 17)
ns of over-the counter (OTC) medicines is not statistically different (p-value =
medicines is statistically different (p-value < 0.001). Availability of OB and GE
er for neither OTC nor prescription medicines, in both chain and independent
lue = 0.01) in chain and independent pharmacies. There was no statistically
nes among chain and independent pharmacies. The mean availability of OB
e of both OTC (p-value = 0.001) and prescription (p-value < 0.001) medicines
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equivalents was similar (p-value = 1.00) among the chain
(78.6 %) and independent pharmacies (76.6 %). However,
the OB prescription medicines were relatively less avail-
able (p-value < 0.001) in independent pharmacies
(28.6 %) as compared to the chain counterparts (52.7 %).
In the case of OTC medicines, both the OB and gen-
eric equivalent medicines were statistically (p-value =
0.01) more available in chain pharmacies (80.9 and
94.5 %, respectively) as compared to those in independ-
ent pharmacies (63.6 and 72.7 %, respectively). See
Additional file 1: Tables S1–S4.Facility survey: price of surveyed medicines
Over-the-counter medicines
Table 3 summarizes the MPRs of the surveyed OTC
medicines. Overall, across all medicines in the analysis
(Table 3a), the OB and LPG versions of surveyed OTC
medicines were priced 21.33 (range: 11.41–41.24) and
11.53 (2.68–29.42) times the IRPs, respectively. Cimeti-
dine had the highest MPR among both the OB (MPR:
41.24) and LPG medicines (MPR: 29.42). Loratadine and
clotrimazole had the lowest MPRs among the OB and
LPG medicines, which were 11.41 and 2.68 respectively.
The analysis of matched pairs (Table 3b) showed that
overall the OB and LPG versions of the same products were
priced 21.33 and 14.56 times the IRP respectively. The me-
dian price premium for OB versions was 46.5 % (range:
23.4–133.8 %) over the LPG price. In the case of both chain
and independent pharmacies, the median MPRs of the OB
were statistically higher (chain p-value = 0.008; independent
p-value = 0.03) than that of the LPG medicines.Table 3 Summary of median price ratios (MPR) of the surveyed ove








Median MPR 21.33 11.53 20.81
Minimum, Maximum
MPR
11.41, 41.24 2.68, 29.42 11.41, 1
3(b). Matched pair analysis
Originator Brand Lowest Price Generic Origina
OB-LPG pairs = 9 OB-LPG
Median MPR 21.33 14.56 20.81
Minimum, Maximum MPR 11.41, 41.24 5.40, 29.42 11.41, 1
In 'all medicines' analysis, the overall median MPRs for the originator brand (OB) an
were marginally different (p-value = 0.056). In chain pharmacies, the median MPRs o
Whereas in the independent pharmacies, the median MPRs of the OB and LPG wer
OB version of OTC medicine in chain pharmacy were not statistically different (p-va
of the LPG versions were marginally different (p-value = 0.503) among the chain an
In 'matched pair' analysis, the overall median MPRs of the OB and LPG versions of O
and independent pharmacies, the median MPRs of the OB and LPG versions of OTC
p-value = 0.03) from each otherAcross all medicines in the analysis, the unit price of
OB medicines was 15.7 % higher in chain pharmacies
than in independent pharmacies. The price of LPG med-
icines was 22.3 % higher in chain pharmacies than in in-
dependents. In the matched pairs analysis, the median
MPRs of both OB and LPG versions of OTC medicines
were higher in chain pharmacies as compared to
independent pharmacies, however, the differences were
not statistically significant (OB p-value = 0.81; LPG p-
value = 0.20). Also see Additional file 1: Tables S5 and S7.Prescription medicines
Across ‘all medicines’ (Table 4a), the OB and LPG ver-
sions of prescription medicines were 158.14 (range:
16.43–655.09) and 38.03 (12.52–155.46) times, respect-
ively, the IRPs. Considering LPG versions, the median
MPR in chain pharmacies (39.54) was higher than that
in independent pharmacies (31.28), though this differ-
ence was not statistically significant (p-value = 0.31). In
contrast, the median MPR for OB versions was higher in
independent pharmacies (188.56) than in chain pharma-
cies (180.29), however no significant difference was
found (p-value = 0.86). Notably, the MPR was calculated
for only three prescription medicines pairs in independ-
ent pharmacies due to low availability.
In ‘matched pair’ analysis (Table 4b), the median MPRs
of the OB and LPG versions of prescription medicines
were statistically different from each other, both overall
and within chain pharmacies. The median OB price pre-
mium was 299.1 % over the LPG price, ranging to as
high as 1943.2 % in case of diazepam. Also see











43.13 2.68, 112.08 11.69, 37.27 2.55, 31.58
tor Brand Lowest Price Generic Originator Brand Lowest Price Generic
pairs = 9 OB-LPG pairs = 8
15.81 17.81 9.50
43.13 5.79, 112.08 11.69, 35.15 3.55, 31.58
d lowest price generic (LPG) versions of the over-the-counter (OTC) medicines
f the OB and LPG versions were not statistically different (p-value = 0.11).
e statistically different (p-value = 0.004). Furthermore, the median MPRs of the
lue = 0.96) from that in the independent pharmacy. Similarly, the median MPRs
d independent pharmacies.
TC medicines were statistically different (p-value = 0.03). Within both chain
medicines were statistically different (chain p-value = 0.008; independent
Table 4 Summary of median price ratios (MPR) of the surveyed prescription medicines in retail pharmacies
4(a). All Medicines analysis













Median MPR 158.14 38.03 180.29 39.54 188.56 31.28
Minimum, Maximum
MPR




Originator Brand Lowest Price Generic Originator Brand Lowest Price Generic
OB-LPG pairs = 10 OB-LPG pairs = 8
Median MPR 158.14 35.15 180.29 39.54
Minimum, Maximum
MPR
16.43, 655.09 12.52, 98.57 29.29, 663.30 28.73, 115.79
In 'all medicines' analysis, overall median MPRs of originator brand (OB) and lowest price generic (LPG) versions of the prescription medicines were statistically
different (p-value = 0.04). In chain pharmacies, the median MPRs of OB and LPG versions were statistically different (p-value < 0.05). Significance could not be
calculated among independent pharmacies due to low availability of originator products.
In 'matched pair' analysis, too few pairs of sampled prescription medicines were available in independent pharmacies to make meaningful comparisons within such facilities.
The overall median MPRs of the OB and LPG versions of prescription medicines were statistically different (p-value = 0.03), both overall and in case of chain pharmacies
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Inclusion
Table 5 summarizes medicine inclusion and prices in
pharmacy discount programs. Among the seven phar-
macy discount programs surveyed, the overall inclusion
percentage of studied medicines was variable, ranging
from 42.3 % (Walmart/Sam’s Club and Target $4/$10
program) to 100 % (Target prescription saver program).
Overall, acute medicines were more frequently included
than chronic medicines, with a mean inclusion of 71.4 %
compared to 60.2 %, respectively. All pharmacy discount
programs had higher acute medicine inclusion than
chronic, except for the higher-priced Target prescription
saver program, where 100 % of surveyed acute and
chronic medicines were included.
Prices
Table 5 shows that among the surveyed pharmacy discount
programs, the median of the MPR in which the discount
program prices were compared to IRPs for the acute and
chronic medicines were found to be 8.3 (range: 4.4–16.3)
and 5.0 (4.1–13.7), respectively. Walmart/Sam’s Club and
target $4/10 discount programs had the lowest overall MPR
of the programs at 4.4 (range: 3.3–18.8), whereas Target
Prescription saver had the highest MPR of the programs at
13.9 (range: 2.9–81.3). Also see Additional file 1: Table S9.
Limitations of the study
Despite the strengths of the WHO/HAI methodology,
there are some limitations of this study. First, we
assessed the availability and prices for a specific list of
medicines and did not account for other strengths,dosage forms or therapeutic alternatives. Due to the low
availability of OB prescription products in independent
pharmacies, we were unable to undertake meaningful
‘matched pair’ analysis of all prices. All pharmacists re-
ported it would take them less than 24 hours to obtain
specific prescription medicines that were not available
in-store. In the case of the pharmacy discount programs,
we assessed if a medicine was included in a given pro-
gram but did not assess the physical availability for dis-
pensing at the respective pharmacies. Also, our analysis
is based on the data collected on the day of survey and
may not indicate availability and prices over time. In
addition, we did not account for any discounts or insur-
ance, which vary by patient. Lastly, the results of the fa-
cility study may not represent medicine availability and
prices in other US states, however we provide an initial
reference point for future studies to be conducted in
North America.
Discussion
To our best knowledge, this is the first WHO/HAI study
to assess the availability and prices of essential medicines
in private-sector retail pharmacies in the US. The avail-
ability of medicines is often suboptimal around the
globe, for medicines to treat both chronic and acute
conditions [9]. An analysis of findings from price and
availability surveys conducted in 36 developing and
middle-income countries in 2009 found the average
availability of generics was 64 % in the private sector.
Availability was very low in some countries (e.g. Chad
14 %, Philippines 34 %, Shangdong province, China
35 %) but good in others (e.g. Syria 98 %, Chennai, India
Table 5 Inclusion and price ratio of studied medicines in the pharmacy discount program
Type of Medicine Walmart/Sam’s Club Target Prescription
Saver
















































































































aInclusion refers to the percentage of total surveyed medicines offered by a given pharmacy discount program
bCompares median of the calculated price ratios to the MSH median unit reference price
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nerics ranged from 152 % in the private sector in upper-
middle income countries to over 300 % in low-income
countries [9].
In our study, while few patients pay full list prices,
assessing the actual prices paid was not possible given
that discounts are highly variable and cannot be stan-
dardized. While it is possible to assess individual level
prices paid using prescription claims data, this data does
not include the population of interest, such as patients
without health insurance (~33 million i.e. 10.4 % of
people in the US in 2014) [30] and/or those who pay
OOP. Furthermore, as mentioned earlier, more people
are opting for high deductible insurance plans; the num-
ber increased from 11.4 million in 2011 to 15.5 million
in 2013. Notably 49 % of these people were age 40 and
over, an age group with expectedly higher healthcare
and prescription needs [31].
Results of our survey show that overall availability was
similar to WHO’s target of 80 %, except for OB prescrip-
tion medicines, which had lower availability, especially
in independent pharmacies. This may be due to several
factors, including independent pharmacies’ ability to
procure OB prescription medicines quickly, low demand
for such products, as well as the consumer and insurer
trend towards purchasing generics whenever possible.
Notably, availability was assessed in an environment
with a highly developed supply chain, where pharmacies
routinely request and can avail less commonly pre-
scribed medications within several hours from other
sources as needed. In such cases, availability is not an
absolute barrier to access. However, it can become a bar-
rier to access when considering that some patients may
not return to retrieve their medicines due to the incon-
venience of returning. Furthermore, availability estimates
reflect the market, reflecting difference in availability of
OB medicines among chain and independent pharma-
cies. Mail-order pharmacies were not included in this
study, however, they will impact the overall availability
of medicines for patients. Our results were consistent
with the Consumer Reports findings which showed sub-
stantial price variations across pharmacies, and that sav-
ings were realized when patients purchased certain
generic medicines at big box-stores such as Walmart
and Target and pharmacy discount programs, paying a
discounted retail price [26–28].
While noting the WHO target that consumers should
pay no more than four times the IRPs, we observed that
medicine prices were high in the Boston area compared
to IRPs. The OB and generic versions of OTC medicine
prices in Boston area were as high as 21.33 and 14.56
times the MSH IRPs, respectively. The prices of pre-
scription medicines were particularly high, with OB and
generic versions at 158.14 (range 16.43–655.09) and38.03 (12.52–155.46) times the IRP, respectively. These
patient prices in Boston for the prescription medicines
were very high when compared to the prices paid for the
same 14 medicines in the private sector of some other
high-income countries. A medicine price survey in
Bahrain, undertaken in 2013 using the WHO/HAI meth-
odology, showed that patients were paying 34.78 and
13.85 times IRPs for OBs and LPG respectively. In 2011 in
Tatarstan Province in Russia, patients were paying 13.05
and 4.12 times IRPs for OB and LPG respectively. In 2010
in a high-income Caribbean country, patients were paying
61.44 and 17.33 times IRPs for OB and LPG respectively
[22]. While the data was not adjusted for purchasing
power parity, it is clear that patient prices in Boston were
substantially higher than in these three countries.
Interestingly, the OTC medicines were cheaper in in-
dependent pharmacies than in chain pharmacies. Al-
though the OB prescription medicines were higher
priced in independent pharmacies, LPGs were higher
priced in the chain pharmacies. A contributing factor
may be the recent increased cost to register a generic
medicine in the US [32].
While the prices obtained in this survey may seem high
in relation to the IRPs, most patients receive insurance as-
sistance or discounts from their health payer for prescrip-
tion medicines (but not OTC medicines). For many of the
prescription medicines surveyed, pharmacy discount pro-
grams are available. With the wide range in insurance as-
sistance and discounts across health insurance plans and
by product, consumers generally do not know what they
will be expected to pay for a medicine when dispensed at
the pharmacy using insurance. This lack of transparency
can be disadvantageous for consumers. For uninsured
patients, while it would be desirable to fill prescriptions
through pharmacy discount programs, we don’t know if
they are directed to these programs. Consumer Reports
suggests that this is not the case [26].
This survey has been conducted in an intensely medi-
calized and urban environment. It is not clear what the
results would be in other settings. The Boston survey
will be conducted annually using the same methods to
evaluate trends in medicine availability and price over
time. It would be of interest to have similar surveys re-
peated in other areas to compare results.
Prescribers in the US should encourage consumers to
consider the pharmacy discount programs, which offer
generic medicines at lower prices. Unlike the facilities,
the prices of medicines in the pharmacy discount pro-
grams were much closer to WHO’s target of four times
the IRPs. Our analysis shows that the cheapest medi-
cines, when not using insurance, are from the discount
programs offered in big-box retail stores and in-store
and free standing pharmacies. However, inclusion of a
medicine in a given pharmacy discount program and the
Sharma et al. Journal of Pharmaceutical Policy and Practice  (2016) 9:12 Page 10 of 11price offered varied across programs, providing a reason
for consumers to shop around.
If the policy in the US is not to regulate medicine prices,
but rather rely on retail price competition, then a transpar-
ent system is needed that allows consumers to easily check
prescription medicine prices at different pharmacies in order
to identify potential savings. These benefits will need to be
balanced against the cost of membership fees and the chal-
lenges of travel to sites with discounted prices. Consumers
must be empowered to choose facilities and payment op-
tions most beneficial to them, whether that’s paying with in-
surance at a traditional pharmacy, or foregoing insurance
co-payments and opting for discounted medicines through
pharmacy discount programs or other options. However,
such decisions cannot be made without transparent prices
that allow for comparison. The current lack of transparency
even extended to our survey where 6 pharmacies (4 inde-
pendent and 2 chains) failed to provide full price informa-
tion for the prescription medicines surveyed.
Conclusion
The responsibility for ensuring price transparency rests
primarily with policy-makers. Comprehensive policies are
needed that are legally binding. Consumers (as well as
healthcare providers and others) must be able to easily ac-
cess regularly updated medicine price information in
order to make informed decisions about the treatments.
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